Evidence map›Paper›PMID 39570460›Full record

SynthesisInternational journal of clinical oncology2025

Clinical benefits of adding olanzapine to 5-HT

Michiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, Masakazu Abe, Junichi Nishimura, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K Imamura and 18 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  3. Observational
  4. Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Michiyasu MurakamiDepartment of Pharmacy, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan. muramichi1959@gmail.com.ORCID http://orcid.org/0009-0004-9331-2210
Yoshiharu MiyataDepartment of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, 7-1-48 Minatojimaminamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Kazuhisa NakashimaDepartment of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, Japan.
Masakazu AbeDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1‑20‑1 Handayama, Chuo‑Ku, Hamamatsu, Shizuoka, 431‑3192, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1‑69, Osaka, 541‑8567, Japan.
Makoto WadaDepartment of Pscho-Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1‑69, Chuo-Ku, Osaka, 541‑8567, Japan.
Keiko IinoSchool of Nursing, National College of Nursing, 1‑2‑1, Umezono, Kiyose, Tokyo, 204‑8575, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive‑Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho‑Cho, Mizuho‑Ku, Nagoya, 467‑8601, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1‑1 Yanagido, Gifu, Gifu, 501‑1194, Japan.
Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa University, 1‑5‑8 Hatanodai, Shinagawa‑Ku, Tokyo, 142‑8555, Japan.
Ayako OkuyamaGraduate School of Nursing Science, St. Luke's International University, 10‑1 Akashi‑Cho, Chuo‑Ku, Tokyo, 104‑0044, Japan.
Keiko OzawaDivision of Survivorship Institute for Cancer Control, National Cancer Center, 5‑1‑1 Tsukiji, Chuo‑Ku, Tokyo, 104‑0045, Japan.
Yong-Il KimDivision of Medical Oncology, Yodogawa Christian Hospital, 1‑7‑50 Kunijima, Higasiyodogawa‑Ku, Osaka, Osaka, 533‑0024, Japan.
Hidenori SasakiDivision of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7‑45‑1, Nanakuma, Jonan‑Ku, Fukuoka, 814‑0180, Japan.
Eriko SatomiDepartment of Palliative Medicine, National Cancer Center Hospital, 5‑1‑1 Tsukiji Chuo‑ku, Tokyo, 104‑0045, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Ryuhei TanakaDepartment of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398‑1 Yamane, Hidaka, Saitama, 350‑1298, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.
Mayumi NodaNon-Profit Organizaition Sasaeau-Kai"Alpha", 518‑7 Kawado‑Cho, Chuo‑Ku, Chiba, Chiba, 260‑0802, Japan.
Kazumi HayashiDepartment of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3‑25‑8 Nishi‑Shinnbashi Minatoku, Tokyo, 105‑8461, Japan.
Takahiro HigashiDepartment of Public Health and Health Policy, The University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑0033, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4‑6‑1 Shiroganedai, Minato‑Ku, Tokyo, 108‑8639, Japan.
Koji MatsumotoDivision of Medical Oncology, Hyogo Cancer Center, 13‑70 Kitaoji‑Cho, Akashi, Hyogo, 673‑0021, Japan.
Yoko MatsumotoNon-Profit Organization Ehime Cancer Support Orange-No-Kai, 3‑8‑24 Furukawaminami, Matsuyama, Ehime, 790‑0943, Japan.
Kenji OkitaDepartment of Surgery, Otaru Ekisaikai Hospital, 1‑4‑1, Inaho, Otaru, Hokkaido, 047‑0032, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, 811‑1 Kimiidera, Wakayama, Wakayama, 641‑8509, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto‑Machi, Matsuyama, Ehime, 791‑0280, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlanzapine is an atypical antipsychotic drug used for chemotherapy-induced nausea and vomiting. It is particularly effective in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy (HEC). However, it has side effects, such as hyperglycemia and somnolence, the efficacy and safety of adding olanzapine to triplet antiemetic therapy (5-HT

methodsWe performed a systematic review and meta-analysis to compare the effectiveness of olanzapine combined with triplet antiemetic therapy and triplet antiemetic therapy in preventing nausea and vomiting for HEC. We set five items (hyperglycemia, prevention of vomiting, prevention of nausea, adverse events, and cost (drug costs)) as outcomes and conducted a systematic review.

resultsFive randomized controlled trials was extracted and they showed that the addition of olanzapine was effective in control of nausea and vomiting, especially in the delayed phase. Complete response of acute and delayed phase were significantly higher in the olanzapine group. Risk difference was - 0.14 [95% CI - 0.26, - 0.03; p = 0.02] and - 0.14 [95% CI - 0.19, -0.09; p < 0.00001], respectively. Additionally, we evaluated hyperglycemia and somnolence, which are typical side effects of olanzapine. However, the incidence of grade ≥ 2 was low in both events, and there was no significant difference between olanzapine and control groups.

conclusionsAdding olanzapine to triplet antiemetic therapy is useful in preventing nausea and vomiting induced by HEC and there would be minimal adverse effects from the combination use.

Indexed as

AntiemeticsAntineoplastic AgentsDexamethasoneNauseaOlanzapineSerotonin 5-HT3 Receptor AntagonistsVomitingDrug Therapy, CombinationHumansJapanNeoplasmsNeurokinin-1 Receptor AntagonistsRandomized Controlled Trials as TopicAntiemeticsAntineoplastic AgentsDexamethasoneNeurokinin-1 Receptor AntagonistsOlanzapineSerotonin 5-HT3 Receptor AntagonistsAntiemeticsChemotherapy-induced nausea and vomitingHighly emetogenic chemotherapyMeta-analysisOlanzapineSystematic review

Identifiers

PMID39570460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.